193 related articles for article (PubMed ID: 37133731)
1. SEOM clinical guideline on heritable TP53-related cancer syndrome (2022).
Sánchez-Heras AB; Ramon Y Cajal T; Pineda M; Aguirre E; Graña B; Chirivella I; Balmaña J; Brunet J;
Clin Transl Oncol; 2023 Sep; 25(9):2627-2633. PubMed ID: 37133731
[TBL] [Abstract][Full Text] [Related]
2. Li-Fraumeni and Li-Fraumeni-like syndrome among children diagnosed with pediatric cancer in Southern Brazil.
Giacomazzi J; Selistre SG; Rossi C; Alemar B; Santos-Silva P; Pereira FS; Netto CB; Cossio SL; Roth DE; Brunetto AL; Zagonel-Oliveira M; Martel-Planche G; Goldim JR; Hainaut P; Camey SA; Ashton-Prolla P
Cancer; 2013 Dec; 119(24):4341-9. PubMed ID: 24122735
[TBL] [Abstract][Full Text] [Related]
3. A novel p.Gly187Arg TP53 variant appears to result in Li-Fraumeni syndrome.
Doyle MR; Johnston JM
Pediatr Hematol Oncol; 2018 Apr; 35(3):203-207. PubMed ID: 30239254
[TBL] [Abstract][Full Text] [Related]
4. Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort.
Mai PL; Best AF; Peters JA; DeCastro RM; Khincha PP; Loud JT; Bremer RC; Rosenberg PS; Savage SA
Cancer; 2016 Dec; 122(23):3673-3681. PubMed ID: 27496084
[TBL] [Abstract][Full Text] [Related]
5. TP53 and CDKN1A mutation analysis in families with Li-Fraumeni and Li-Fraumeni like syndromes.
Andrade RC; Dos Santos AC; de Aguirre Neto JC; Nevado J; Lapunzina P; Vargas FR
Fam Cancer; 2017 Apr; 16(2):243-248. PubMed ID: 27714481
[TBL] [Abstract][Full Text] [Related]
6. Clinical spectrum of Li-Fraumeni syndrome/Li-Fraumeni-like syndrome in Brazilian individuals with the TP53 p.R337H mutation.
Ferreira AM; Brondani VB; Helena VP; Charchar HLS; Zerbini MCN; Leite LAS; Hoff AO; Latronico AC; Mendonca BB; Diz MDPE; de Almeida MQ; Fragoso MCBV
J Steroid Biochem Mol Biol; 2019 Jun; 190():250-255. PubMed ID: 30974190
[TBL] [Abstract][Full Text] [Related]
7. Genotype-phenotype associations within the Li-Fraumeni spectrum: a report from the German Registry.
Penkert J; Strüwe FJ; Dutzmann CM; Doergeloh BB; Montellier E; Freycon C; Keymling M; Schlemmer HP; Sänger B; Hoffmann B; Gerasimov T; Blattmann C; Fetscher S; Frühwald M; Hettmer S; Kordes U; Ridola V; Kroiss Benninger S; Mastronuzzi A; Schott S; Nees J; Prokop A; Redlich A; Seidel MG; Zimmermann S; Pajtler KW; Pfister SM; Hainaut P; Kratz CP
J Hematol Oncol; 2022 Aug; 15(1):107. PubMed ID: 35974385
[TBL] [Abstract][Full Text] [Related]
8. Analysis of the Li-Fraumeni Spectrum Based on an International Germline TP53 Variant Data Set: An International Agency for Research on Cancer TP53 Database Analysis.
Kratz CP; Freycon C; Maxwell KN; Nichols KE; Schiffman JD; Evans DG; Achatz MI; Savage SA; Weitzel JN; Garber JE; Hainaut P; Malkin D
JAMA Oncol; 2021 Dec; 7(12):1800-1805. PubMed ID: 34709361
[TBL] [Abstract][Full Text] [Related]
9. Rectal leiomyosarcoma as the initial phenotypic manifestation of Li-Fraumeni-like syndrome: a case report and review of the literature.
Severino NP; Waisberg J; Fragoso MCBV; de Lima LGCA; Balsamo F; Henriques AC; Bianco B; de Sousa Gehrke F
J Med Case Rep; 2022 Dec; 16(1):468. PubMed ID: 36529791
[TBL] [Abstract][Full Text] [Related]
10. Report of 2 Pediatric Cases With Li-Fraumeni Syndrome Related Malignancy in a Family.
Takeoka M; Toyoda H; Hirayama J; Suzuki N; Hanaki R; Amano K; Iwamoto S; Hirayama M
J Pediatr Hematol Oncol; 2021 May; 43(4):e567-e570. PubMed ID: 32555031
[TBL] [Abstract][Full Text] [Related]
11. TP53 germline mutations in adult patients with adrenocortical carcinoma.
Herrmann LJ; Heinze B; Fassnacht M; Willenberg HS; Quinkler M; Reisch N; Zink M; Allolio B; Hahner S
J Clin Endocrinol Metab; 2012 Mar; 97(3):E476-85. PubMed ID: 22170717
[TBL] [Abstract][Full Text] [Related]
12. Medical guidelines for Li-Fraumeni syndrome 2019, version 1.1.
Kumamoto T; Yamazaki F; Nakano Y; Tamura C; Tashiro S; Hattori H; Nakagawara A; Tsunematsu Y
Int J Clin Oncol; 2021 Dec; 26(12):2161-2178. PubMed ID: 34633580
[TBL] [Abstract][Full Text] [Related]
13. Diseases Predisposing to Adrenocortical Malignancy (Li-Fraumeni Syndrome, Beckwith-Wiedemann Syndrome, and Carney Complex).
Jouinot A; Bertherat J
Exp Suppl; 2019; 111():149-169. PubMed ID: 31588532
[TBL] [Abstract][Full Text] [Related]
14. A first report of a rare TP53 variant associated with Li-Fraumeni syndrome manifesting as invasive breast cancer and malignant solitary fibrous tumor.
Prejac J; Dedić Plavetić N; Gotovac Jerčić K; Borovečki F
World J Surg Oncol; 2021 Aug; 19(1):254. PubMed ID: 34452612
[TBL] [Abstract][Full Text] [Related]
15. Cancer incidence, patterns, and genotype-phenotype associations in individuals with pathogenic or likely pathogenic germline TP53 variants: an observational cohort study.
de Andrade KC; Khincha PP; Hatton JN; Frone MN; Wegman-Ostrosky T; Mai PL; Best AF; Savage SA
Lancet Oncol; 2021 Dec; 22(12):1787-1798. PubMed ID: 34780712
[TBL] [Abstract][Full Text] [Related]
16. Breast cancer patients suggestive of Li-Fraumeni syndrome: mutational spectrum, candidate genes, and unexplained heredity.
Penkert J; Schmidt G; Hofmann W; Schubert S; Schieck M; Auber B; Ripperger T; Hackmann K; Sturm M; Prokisch H; Hille-Betz U; Mark D; Illig T; Schlegelberger B; Steinemann D
Breast Cancer Res; 2018 Aug; 20(1):87. PubMed ID: 30086788
[TBL] [Abstract][Full Text] [Related]
17. Early detection of adrenocortical carcinoma in a child with Li-Fraumeni syndrome.
Lin MT; Shieh JJ; Chang JH; Chang SW; Chen TC; Hsu WH
Pediatr Blood Cancer; 2009 Apr; 52(4):541-4. PubMed ID: 19101993
[TBL] [Abstract][Full Text] [Related]
18. Guidelines for the Li-Fraumeni and heritable TP53-related cancer syndromes.
Frebourg T; Bajalica Lagercrantz S; Oliveira C; Magenheim R; Evans DG;
Eur J Hum Genet; 2020 Oct; 28(10):1379-1386. PubMed ID: 32457520
[TBL] [Abstract][Full Text] [Related]
19. Clinical and molecular characterization of patients fulfilling Chompret criteria for Li-Fraumeni syndrome in Southern Brazil.
Matzenbacher Bittar C; de Araújo Rocha YM; Vieira IA; Rosset C; Andreis TF; Sartor ITS; Artigalás O; Netto CBO; Alemar B; Macedo GS; Ashton-Prolla P
PLoS One; 2021; 16(9):e0251639. PubMed ID: 34529667
[TBL] [Abstract][Full Text] [Related]
20. p53 signaling pathway polymorphisms, cancer risk and tumor phenotype in TP53 R337H mutation carriers.
Macedo GS; Vieira IA; Vianna FSL; Alemar B; Giacomazzi J; Brandalize APC; Caleffi M; Volc SM; de Campos Reis Galvão H; Palmero EI; Achatz MI; Ashton-Prolla P
Fam Cancer; 2018 Apr; 17(2):269-274. PubMed ID: 28756477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
